Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 14/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.49 |
| ▸ | MTOR | P42345 | 5/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.44 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4916252 | 0.96 | ATR (0.46) | ATRPIK3CAMTORPRKDCPIK3CD | |
| SCHEMBL4796500 | 0.92 | ATR (0.47) | ATRPIK3CAMTORPRKDCPIK3CD | |
| SCHEMBL4725857 | 0.90 | ATR (0.46) | ATRPIK3CAMTORPRKDCPIK3CD | |
| SCHEMBL4913700 | 0.89 | ATR (0.54) | ATRPIK3CAMTORPRKDCATRIP | |
| SCHEMBL4916260 | 0.89 | ATR (0.46) | ATRPIK3CAMTORPRKDCATRIP | |
| SCHEMBL4913243 | 0.85 | ATR (0.42) | ATRPIK3CAMTORPRKDCPIK3CD | |
| SCHEMBL3931106 | 0.83 | ATR (0.44) | ATRPIK3CAMTORPRKDCPIK3CD | |
| SCHEMBL4793956 | 0.83 | ATR (0.50) | ATRPIK3CAMTORPRKDCPIK3CD | |
| SCHEMBL4794333 | 0.81 | ATR (0.44) | ATRPIK3CAMTORPRKDCPIK3CD | |
| SCHEMBL4781403 | 0.80 | ATR (0.51) | ATRPIK3CAMTORPRKDCPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | claimed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | ATR 3201/4885PIK3CA 3607/4885MTOR 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.